Implications of early treatment among Medicaid patients with Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 2, 2014, Pages 214-224

  Geldmacher, David S ^a   Kirson, Noam Y ^b   Birnbaum, Howard G ^b   Eapen, Sara ^b   Kantor, Evan ^b   Cummings, Alice Kate ^b   Joish, Vijay N ^c  

^a The University of Alabama at Birmingham   (United States)

^b ANALYSIS GROUP   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Alzheimer's disease; Early treatment; Long term care; Medicaid costs; Risk of institutionalization

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL SERVICE; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; EARLY TREATMENT; LONG-TERM CARE; MEDICAID COSTS; RISK OF INSTITUTIONALIZATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COST SAVINGS; FEMALE; HEALTH CARE COSTS; HUMANS; INSTITUTIONALIZATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICARE; NEW JERSEY; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84897541441     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.01.015     Document Type: Article

References (31)

1. Alzheimer's Association 2011 Alzheimer's disease facts and figures Alzheimers Dement 7 2011 Available from: http://www.alz.org/downloads/Facts- Figures-2011.pdf
2. L.E. Hebert, P.A. Scherr, J.L. Bienias, D.A. Bennett, and D.A. Evans Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch Neurol 60 2003 1119 1122
3. Early recognition and treatment of dementing disorders. Wisconsin Alzheimer's Institute. c2010 [updated 2010 July 8]. Available at: http://www.wai.wisc.edu/education/msicme/page1.html. Accessed October 19, 2011.
4. D.L. Weimer, and M.A. Sager Early identification and treatment of Alzheimer's disease: social and fiscal outcomes Alzheimers Dement 5 2009 215 226
5. D. Knopman, L. Schneider, K. Davis, S. Talwalker, F. Smith, and T. Hoover et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality Neurology 47 1996 166 177
6. D.S. Geldmacher, G. Provenzano, T. McRae, V. Mastey, and J.R. Ieni Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease J Am Geriatr Soc 51 2003 937 944
7. O.L. Lopez, J.T. Becker, J. Saxton, R.A. Sweet, W. Klunk, and S.T. DeKosky Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition J Am Geriatr Soc 53 2005 83 87
8. H.H. Feldman, T. Pirttila, J.F. Dartigues, B. Everitt, B. Van Baelen, and S. Schwalen et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease Int J Geriatr Psychiatry 24 2009 479 488
9. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, and E. Sellwood et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet 363 2004 2105 2115
10. M. Harriet, H.M. Lamb, and K.L. Goa Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease Pharmacoeconomics 19 2001 303 318
11. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 1987 373 383
12. J.D. Singer, and J.B. Willett It's about time: using discrete-time survival analysis to study duration and the timing of events J Educ Stat 18 1993 155 195
13. Kaiser Commission on Medicaid. Total Medicaid Spending, FY2009. 2011. [cited 2011 Oct 18]. Available from: http://www.statehealthfacts.org/profileind. jsp?ind=177&cat=4&rgn=32.
14. M. Luppa, T. Luck, E. Brähler, H.H. König, and S.G. Riedel-Heller Prediction of institutionalisation in dementia: a systematic review Dement Geriatr Cogn Disord 26 2008 65 78
15. O. Lopez, J. Becker, S. Wisniewski, J. Saxton, D. Kaufer, and S. DeKosky Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease J Neurol Neurosurg Psychiatry 72 2002 310 314
16. M. Becker, R. Andel, L. Rohrer, and S.M. Banks The effect of cholinesterase inhibitors on risk of nursing home placement among Medicaid beneficiaries with dementia Alzheimer Dis Assoc Disord 20 2006 147 152
17. M. Sano A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease N Engl J Med 336 1997 1216 1222
18. S.L. Rogers, R.S. Doody, R.D. Pratt, and J.R. Ieni Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study Eur Neuropsychopharmacol 10 2000 195 203
19. M.S. Mittelman, S.H. Ferris, E. Shulman, G. Steinberg, and B. Levin A family intervention to delay nursing home placement of patients with Alzheimer disease: a randomized controlled trial JAMA 276 1996 1725 1731
20. M.R. Farlow Do cholinesterase inhibitors slow progression of Alzheimer's disease? Int J Clin Pract Suppl 127 2002 37 44
21. K.M. Beursterien, S.K. Thomas, D. Gause, M. Kimel, S. Arcona, and D. Mirski Impact of rivastigmine use on the risk of nursing home placement in a US sample CNS Drugs 18 2004 1143 1148
22. J. Leon, C.-K. Cheng, and P.J. Neumann Alzheimer's disease care: costs and potential savings Health Aff 17 1998 206 216
23. The Lewin Group. Saving lives, saving money: dividends for Americans investing in Alzheimer research. Commissioned by the Alzheimer's Association. Washington, DC; 2004.
24. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
25. G.W. Small, P.V. Rabins, P.P. Barry, N.S. Buckholtz, S.T. DeKosky, and S.H. Ferris et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society JAMA 278 1997 1363 1371
26. W. Max Alzheimer's disease: the unpaid burden of caring J Aging Health 7 1995 179 199
27. H. Feldman, S. Gauthier, J. Hecker, B. Vellas, B. Emir, and V. Mastey et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden J Am Geriatr Soc 51 2003 737 744
28. H.H. Feldman, T. Pirttila, J.F. Dartigues, B. Everitt, B. Van Baelen, and H.R. Brashear et al. Analyses of mortality risk in patients with dementia treated with galantamine Acta Neurol Scand 119 2009 22 31
29. D.C. Goff Jr., D.K. Pandey, F.A. Chan, C. Ortiz, and M.Z. Nichaman Congestive heart failure in the Unites States: is there more than the ICD code? The Corpus Christi Heart Project Arch Intern Med 160 2000 197 202
30. D.H. Taylor, G.G. Fillenbaum, and M.E. Ezell The accuracy of Medicare claims data in identifying Alzheimer's disease J Clin Epidemiol 55 2002 929 937
31. Alliance for Aging Research. The future economic cost of neurological disease. The Silver Book. 2012. Available at: http://www.silverbook.org/browse. php?id=54. Accessed October 18, 2011.